Literature DB >> 12031214

Glatiramer acetate.

G Comi1, L Moiola.   

Abstract

Glatiramer acetate (GA) is a mixture of synthetic polypeptides composed of four aminoacids. GA is very effective in suppression of experimental autoimmune encephalomyelitis (EAE), the animal model of multiple sclerosis (MS). Various mechanisms of action of GA have been proposed, but the most important is probably the induction of antigen-specific suppressor T cells. Class one clinical trials have demonstrated that GA reduces the relapse rate and the accumulation of disability in relapsing-remitting (RR) MS. The positive effects on disease activity and disease progression are explained by the reduction of the number and volume of the active lesions as showed by Magnetic resonance imaging (MRI) studies. Moreover new MRI techniques suggest that GA may also have some neuroprotective effects. The drug is usually well tolerated with modest side effects. In vitro and in vivo animal studies have shown that GA is devoid of teratogenic or mutagenic effects. GA is a good alternative to interferon beta for treatment of RR-MS.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12031214

Source DB:  PubMed          Journal:  Neurologia        ISSN: 0213-4853            Impact factor:   3.109


  2 in total

1.  Glatiramer acetate reduces lymphocyte proliferation and enhances IL-5 and IL-13 production through modulation of monocyte-derived dendritic cells in multiple sclerosis.

Authors:  A Sanna; M L Fois; G Arru; Y-M Huang; H Link; M Pugliatti; G Rosati; S Sotgiu
Journal:  Clin Exp Immunol       Date:  2006-02       Impact factor: 4.330

2.  Gene expression studies of a human monocyte cell line identify dissimilarities between differently manufactured glatiramoids.

Authors:  Sarah Kolitz; Tal Hasson; Fadi Towfic; Jason M Funt; Shlomo Bakshi; Kevin D Fowler; Daphna Laifenfeld; Augusto Grinspan; Maxim N Artyomov; Tal Birnberg; Rivka Schwartz; Arthur Komlosh; Liat Hayardeny; David Ladkani; Michael R Hayden; Benjamin Zeskind; Iris Grossman
Journal:  Sci Rep       Date:  2015-05-22       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.